<DOC>
	<DOCNO>NCT02737787</DOCNO>
	<brief_summary>The purpose study test safety combination investigational WT1 vaccine another drug call nivolumab . This first time WT1 vaccine nivolumab use combination .</brief_summary>
	<brief_title>A Study WT1 Vaccine Nivolumab For Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Pathologic diagnosis ovarian , fallopian tube primary peritoneal cancer confirm pathology review MSK . Patients relapse least returned complete clinical remission additional chemotherapy . Interval surgery permit . Complete clinical remission define CA125 within normal limit , examination CT MRI without objective evidence disease ( non specific abnormality permit radiologic imaging ) . Patients may sign screen consent recurrence time remission start vaccine therapy within 4 month complete chemotherapy . Testing patient 's archive ( paraffin embed , unstained slide ) freshly biopsied tumor nodule must positive WT1 protein expression . WT1 expression : Immunohistochemical analysis perform use technique describe Dupont et al [ 58 ] . WT1 expression grade accord adaptation German Immunoreactive Score ( IRS ) . Only tumor moderate strong IRS score ( 412 ) consider WT1 positive . Age ≥ 18 year Karnofsky performance status ≥ 70 % Hematologic parameter : Absolute neutrophil count ≥ 1000/mcL , Platelets &gt; 50 K/mcL . Biochemical parameter : Total bilirubin ≤ 1.5 mg/dl , AST ALT ≤ 2.5 x upper limit normal , Creatinine ≤ 1.5 mg/dl . Patient childbearing potential must negative serum pregnancy test prior study entry must practice effective form birth control Pregnant lactate woman Patients active infection require systemic antibiotic , antiviral , antifungal treatment Patients serious unstable medical illness another active cancer . Patients condition require systemic treatment either corticosteroid ( &gt; 10mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration . Inhaled topical steroid adrenal replacement dos &gt; 10mg daily prednisone equivalent permit absence active autoimmune disease . Patients known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) . Patients know active hepatitis B virus hepatitis C virus acute chronic infection . Patients active know suspected autoimmune disease ( treated hypothyroidism permit enroll ) Patients active interstitial pneumonitis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Second Greater Remission</keyword>
	<keyword>WT1 Analog Peptide Vaccine</keyword>
	<keyword>Montanide</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>15-247</keyword>
</DOC>